Skip to main content
Equibles

Robin Kramer

CFO

Biogen Inc. (BIIB)

Equibles does not estimate personal net worth.

Get an email with a short summary when Biogen Inc. publishes a filing, an earnings call transcript or a press release.

Get BIIB alerts

About Robin Kramer

Robin Kramer is recorded as CFO at Biogen Inc. (BIIB). Biogen Inc. reported in an 8-K filed October 30, 2024 that Robin Kramer was appointed Chief Financial Officer, effective February 28, 2025. The proxy statement of Biogen Inc. reports total compensation of $5,806,584 for Robin Kramer in fiscal 2025, including a base salary of $759,617. Robin Kramer has spoken on 5 earnings calls and 1 other investor event across 1 company, most recently for Biogen Inc. on October 28, 2026. Biogen Inc. is classified in the Drug Manufacturers - General industry within the Healthcare sector. Other leadership on record at Biogen Inc. includes Christopher A. Viehbacher (CEO and Board Member), Caroline D. Dorsa (Chairman), Michael R. McDonnell (CFO) and 7 others.

“Robin Kramer, the Company's Chief Accounting Officer and Head of Global Business Services and Treasury has been appointed Chief Financial Officer effective upon Mr. McDonnell's retirement.”
Biogen Inc. Form 8-K, filed October 30, 2024 · Read the filing

Robin Kramer on recent calls

“I'm pleased to provide our update on another strong quarterly financial performance. Our results reflect the continued momentum in our commercial portfolio that we've seen throughout this year, and Q3 marks the first full quarter with Sifovry and Epivelli in our growth portfolio.”
CFO, Q3 2026 Earnings Call Webcast ·
“It's actually been an incredibly exciting time to be the CFO at Biogen. I've been at the company now almost eight years, but in the CFO role just over a year and a half.”
CFO, Biogen to Present at the Wells Fargo 21st Annual Healthcare Conference ·
“This performance was driven by our growth portfolio, which generated over a billion dollars of revenue in the quarter, up 24% year-over-year and 25% quarter-over-quarter.”
CFO, Biogen Inc. Q2 FY2026 Earnings Call ·
“I'd like to start with key highlights from our strong first quarter 2026 results. Total revenue was $2.5 billion, up 2% year-over-year, with GAAP-diluted EPS of $2.15 up 31% year-over-year, and non-GAAP-diluted EPS of $3.57 up 18% year-over-year.”
CFO, Biogen Inc. Q1 FY2026 Earnings Call ·
“I'd like to provide some key highlights about our strong fourth quarter and full year financial results. Unless otherwise noted, the comparisons I make during my remarks are versus 2024 and refer to non-GAAP unless otherwise stated.”
CFO, Biogen Inc. Q4 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at Biogen Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Biogen Inc. (BIIB) $759,617 $5,806,584

Recent activity